Home
Productsindex
Gene
mRNA Productsindex
mRNAs for Cancer Vaccine Researchlists
VHL35 Circular RNA for Cancer Vaccine Research
CVAC-ORNA-0001
VHL35 Circular RNA for Cancer Vaccine Research
Source:In vitro transcribed mRNA was further circularized to make this product as a circular RNA.
Alternative Names:(H115D)VHL35 Peptide
SKU:CVAC-ORNA-0001-LNP
Product Name:VHL35 Circular RNA-LNP for Cancer Vaccine Research
Product Description:ALG-ORNA-0001 was encapsulated with lipid nanoparticles through Seattle Genova's LipoX platform.
SKU:CVAC-ORNA-0001
Product Name:VHL35 Circular RNA for Cancer Vaccine Research
Product Description:In Vitro Transcribed mRNA template encoding VHL35 was further circularized with Seattle Genova's OSTAR technology. The resulting circRNAs are very stable and have low immunogenicity enabling prolonged protein translation in different cells without cellular toxicity.
SKU:CVAC-ORNA-0001-LNP
Product Name:VHL35 Circular RNA-LNP for Cancer Vaccine Research
Product Description:ALG-ORNA-0001 was encapsulated with lipid nanoparticles through Seattle Genova's LipoX platform.
SKU:CVAC-ORNA-0001
Product Name:VHL35 Circular RNA for Cancer Vaccine Research
Product Description:In Vitro Transcribed mRNA template encoding VHL35 was further circularized with Seattle Genova's OSTAR technology. The resulting circRNAs are very stable and have low immunogenicity enabling prolonged protein translation in different cells without cellular toxicity.
PROPERTIES
5'-UTR:
5' -untranslated region derived from human alpha-globin RNA with an optimized Kozak sequence
ORF:
VHL35
3'-UTR:
3' UTR comprising two sequence elements derived from the aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA
Modifications:
N1-methyl-pseudouridine
Neutral Lipid:
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)
Cholesterol:
Cholesterol
Lonizable Lipid:
1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)
PEG-lipid:
Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)− 8-oxooctyl)amino)octanoate)(SM-102)
Storage:
-80 °C
Buffer:
PBS, pH7.5
Cryoprotectant:
Trehalose
Background

Gene Alias

(H115D)VHL35 Peptide

Background

Description: A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. In (H115D)VHL35 peptide, histidine is substituted for an aspartic acid in position 115. It might be used to elicit or boost cellular immunity to cancers that expressing the von Hippel-Lindau mutation. (NCI04) (NCIT_C28776).

RECOMMENDED PRODUCTS
BioActive Human ABL1 (V299L,T315A,F317L,F317V,F317I,F317C) Recombinant Protein,Fc Tag
ABL1

SGRP00624

BioActive Human ABL1 (V299L,T315A,F317L,F317V,F317I,F317C) Recombinant Protein,Fc Tag
View Price and Availability
BioActive Human ABL1 (T315A,F317L,F317V,F317I,F317C,V299L) Recombinant Protein,Fc Tag
ABL1

SGRP00628

BioActive Human ABL1 (T315A,F317L,F317V,F317I,F317C,V299L) Recombinant Protein,Fc Tag
View Price and Availability
BioActive Human AKT1 (Q79K,E17K) Recombinant Protein,Fc Tag
AKT1

SGRP00630

BioActive Human AKT1 (Q79K,E17K) Recombinant Protein,Fc Tag
View Price and Availability
BioActive Human AKT1 (H238Y) Recombinant Protein,Fc Tag
AKT1

SGRP00631

BioActive Human AKT1 (H238Y) Recombinant Protein,Fc Tag
View Price and Availability
BioActive Human ALK (G1123S) Recombinant Protein,Fc Tag
ALK

SGRP00637

BioActive Human ALK (G1123S) Recombinant Protein,Fc Tag
View Price and Availability
0.198835s